Skip to main content
TipRanks
Go Ultimate75% OFF

RegenXBio (RB0) Stock Price & Analysis

1 Followers

RB0 Stock Chart & Stats

€7.14-€0.29(-3.93%)
At close: 5:30 PM GMT+1
€7.5€10€12.5Jun 1Jun 22Jun 29Jul 6Aug 6Aug 10Aug 28
Day’s Range
EUR 7.14 - EUR 7.14
52-Week Range
EUR 4.73 - EUR 13.60
Previous Close
EUR 7.43
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 458.32M
Enterprise Value
EUR 492.45M
Total Cash (Recent Filing)
EUR 250.98M
Total Debt (Recent Filing)
EUR 66.55M
Price to Earnings (P/E)
―
Beta
1.46
Next Earnings
Mar 02, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

AAV Platform And Partnerships

REGENXBIO combines an AAV technology platform with internal programs and partner arrangements, creating multiple routes to future revenue. Licensing, milestones, royalties and collaboration payments can diversify commercialization outcomes while extending the platform’s strategic value across serious genetic diseases.

Liquidity And Operating Runway

The reported liquidity position is intended to fund operations through late 2027 under current plans, allowing the company to advance major clinical and regulatory programs without immediate financing pressure. This supports execution through several important milestones and provides greater planning flexibility.

Late-stage Pipeline And Commercial Readiness

Multiple late-stage programs give REGENXBIO several potential paths toward product revenue rather than relying on a single early research asset. Progress toward pivotal readouts, a BLA and commercialization preparation could materially expand the company’s strategic position if clinical and regulatory execution succeeds.

Bears Say

Persistent Losses And Cash Burn

Substantial operating and free-cash-flow deficits show that the current business is consuming capital rather than funding development internally. Continued losses increase dependence on existing liquidity, future financing or partner payments, while potentially limiting flexibility if clinical timelines extend or outcomes disappoint.

RGX-121 Clinical And Regulatory Uncertainty

The RGX-121 clinical hold creates a durable obstacle for a program targeting Hunter Syndrome and leaves its regulatory trajectory unresolved. Ongoing imaging and follow-up may delay development, reduce the program’s near-term contribution, and require management to redirect resources toward other pipeline assets.

Reduced ZOLGENSMA Royalty Protection

Expiration of U.S. ZOLGENSMA intellectual property reduces the geographic coverage of an established royalty stream and increases reliance on other sources such as ITVISMA and future milestones. This can make partner-derived revenue less predictable while internal candidates remain unapproved.

RegenXBio News

RB0 FAQ

What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was €4.73 and its highest was €13.60 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is €458.32M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 106 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on Nov 05, 2026. The company reported -€0.555 earnings per share for the quarter, beating the consensus estimate of -€1.152 by €0.597.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -0.86.
How many shares outstanding does RegenXBio have?
RegenXBio has 66,122,600 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of -€0.555 in its last earnings report, beating expectations of -€1.152. Following the earnings report the stock price went up 0.93%.
Which hedge fund is a major shareholder of RegenXBio?
Hedge funds hold RegenXBio shares: the largest hedge-fund position in RegenXBio is 1,730,971,293 shares, and hedge funds decreased their holdings by 12.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology